Search

Your search keyword '"Bouscambert-Duchamp M"' showing total 98 results

Search Constraints

Start Over You searched for: Author "Bouscambert-Duchamp M" Remove constraint Author: "Bouscambert-Duchamp M"
98 results on '"Bouscambert-Duchamp M"'

Search Results

5. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

11. Herpes simplex type 1 primo-infection and pregnancy, two cases of intra-uterine infection and revue of the literature

16. In vitro characterization of naturally occurring influenza H3NA− viruses lacking the NA gene segment: Toward a new mechanism of viral resistance?

28. Increased detection of Mycoplasma pneumoniae infection in children, Lyon, France, 2010 to 2011

29. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

30. Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial.

31. Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial.

32. Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients.

33. Rapid and reliable inactivation protocols for the diagnostics of emerging viruses: The example of SARS-CoV-2 and monkeypox virus.

34. Additional value of chest CT AI-based quantification of lung involvement in predicting death and ICU admission for COVID-19 patients.

35. Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19.

36. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.

37. T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19.

38. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

39. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.

40. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial.

41. Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19.

42. Placental lesions and SARS-Cov-2 infection: Diffuse placenta damage associated to poor fetal outcome.

43. Performance of Self-Collected Saliva Testing Compared with Nasopharyngeal Swab Testing for the Detection of SARS-CoV-2.

44. Chest CT for rapid triage of patients in multiple emergency departments during COVID-19 epidemic: experience report from a large French university hospital.

45. Cluster of Coronavirus Disease 2019 (COVID-19) in the French Alps, February 2020.

46. Clinical and virological data of the first cases of COVID-19 in Europe: a case series.

47. The NS Segment of H1N1pdm09 Enhances H5N1 Pathogenicity in a Mouse Model of Influenza Virus Infections.

48. Genetic characterization of respiratory syncytial virus highlights a new BA genotype and emergence of the ON1 genotype in Lyon, France, between 2010 and 2014.

49. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.

50. Influenza vaccine effectiveness among adult patients in a University of Lyon hospital (2004-2009).

Catalog

Books, media, physical & digital resources